Systemically Delivered / Locally Activated

ODCs are conditionally activated cytokine therapies

ODCs are engineered for optimal retention and targeted activation at the disease site

ODCs safely trigger cancer-fighting immune cells

Read More About Us

Our Team

Phillip Kim PhD, MBA
CEO, Chairman of the Board

Emma Langley, PhD
COO, VP Research & Development

Hsieng Lu, PhD
Chief Development Advisor

Maria Ramirez, PhD
Head, Clinical Development

Latest News

View all
  • Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Led by Phillip Kim, Ph.D., MBA, Founder and […]

    Continue reading
  • Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines […]

    Continue reading
  • Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal […]

    Continue reading